Trade Names:Cleocin- Capsules 75 mg- Capsules 150 mg- Capsules 300 mgDalacin C (Canada)Clindamycin Palmitate Hydrochloride
Trade Names:Cleocin Pediatric- Granules for oral solution 75 mg per 5 mLClindamycin Phosphate
Trade Names:Cleocin- Vaginal ovules 100 mg- Vaginal cream 2%
Trade Names:Cleocin Phosphate- Injection 150 mg/mL
Trade Names:Cleocin Phosphate IV- Injection 300 mg- Injection 600 mg- Injection 900 mg
Trade Names:Cleocin T- Gel 1%- Lotion 1%- Solution, topical 1%
Trade Names:Clindagel- Gel 1%
Trade Names:ClindaMax- Gel 1%- Lotion, topical 1%
Trade Names:ClindaReach- Solution, topical 1%
Trade Names:Clindesse- Vaginal cream 2%
Trade Names:Clindets- Suspension, topical 1%
Trade Names:Evoclin- Foam 1%Apo-Clindamycin (Canada)Clindasol (Canada)Clinda-T (Canada)Dalacin C Flavored Granules (Canada)Dalacin C Phosphate Sterile Solution (Canada)Dalacin T Topical Solution (Canada)Dalacin Vaginal Cream (Canada)Gen-Clindamycin (Canada)ratio-Clindamycin (Canada)Taro-Clindamycin (Canada)
Suppresses bacterial protein synthesis.
Rapidly absorbed. C max is 2.5 mcg/mL. T max is 45 min. Bioavailability is 90%.IM
T max is 3 h (adults) and 1 h (children).IV
C max is 7 to 14 mcg/mL.Vaginal
About 5% is absorbed (cream); 30% absorbed (suppositories).
Widely distributed (including bones); no significant levels attained in CSF. Excreted in breast milk.
Rapidly converted to active clindamycin.
The average biological half-life is 2.4 to 3.2 h. About 10% of bioactivity is excreted in the urine and 3.6% in the feces; the remainder is excreted as inactive metabolites.
The serum half-life is increased slightly. Dosage adjustment is not usually needed.Hepatic Function Impairment
The serum half-life is increased slightly. Dosage adjustment is not usually needed.
Treatment of serious infections caused by susceptible strains of anaerobic bacteria staphylococci, streptococci, and pneumococci in conditions such as lower respiratory tract infections, skin and skin structure infections, gynecological infections, intra-abdominal infections, septicemia, and bone and joint infections (PO/IV/IM). Treatment of acne vulgaris (topical use). Treatment of bacterial vaginosis (vaginal use) in nonpregnant women and second or third trimester pregnant women ( Cleocin and ClindaMax only).
Alternative to sulfonamides in combination with pyrimethamine in the acute treatment of CNS toxoplasmosis in AIDS patients; treatment of Chlamydia trachomatis infections in women; alternative to metronidazole in the treatment of bacterial vaginosis caused by Gardnerella vaginalis .
Hypersensitivity to lincosamides or any product component; history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.
PO 150 to 450 mg every 6 h.Children Clindamycin hydrochloride
PO 8 to 20 mg/kg/day divided into 3 to 4 doses.Clindamycin palmitate hydrochloride
PO 8 to 25 mg/kg/day divided into 3 to 4 doses. In children weighing 10 kg or less, 37.5 mg 3 times daily should be considered the minimum recommended dosage.AcneAdults
Topical Apply thin film to affected area once daily ( Clindagel , Evoclin ) or twice daily.Acute Pelvic Inflammatory DiseaseAdults
IV 900 mg every 8 h with gentamicin loading dose of 2 mg/kg IV or IM, followed by 1.5 mg/kg every 8 h. Parenteral therapy may be discontinued after 24 h. After discharge from hospital, continue with doxycycline 100 mg twice daily for 10 to 14 days or oral clindamycin 450 mg 4 times daily for 10 to 14 days.Serious InfectionsAdults
PO 150 to 300 mg every 6 hours.More severe infections
PO 300 to 450 mg every 6 h.
IV/IM 600 to 1,200 mg/day in 2 to 4 equally divided doses. For more serious infections, 1,200 to 2,700 mg/day in 2 to 4 equally divided doses may be administered. For severe or life-threatening infections, the dose may be increased. Doses as high as 4,800 mg daily have been given IV. Single IM injections of more than 600 mg are not recommended. Administration of more than 1,200 mg in a single 1-h infusion is not recommended. Alternative dosing may be administered in the form of a single rapid infusion of the first dose followed by continuous IV infusions.To maintain serum levels above 4 mcg/mL
Rapid infusion rate is 10 mg/min for 30 min followed by a maintenance dose of 0.75 mg/min.To maintain serum levels above 5 mcg/mL
Rapid infusion rate is 15 mg/min for 30 min followed by a maintenance dose of 1 mg/min.To maintain serum levels above 6 mcg/mL
Rapid infusion rate is 20 mg/min for 30 min followed by a maintenance dose of 1.25 mg/min.Children 1 mo to 16 yr of age
IV/IM 20 to 40 mg/kg daily in 3 or 4 equally divided doses with the higher doses being given for severe infections. Alternative dosing based on BSA may be considered. 350 mg/m 2 daily for serious infections and 450 mg/m 2 daily for more severe infections.Newborns younger than 1 mo of age
IV/IM 15 to 20 mg/kg daily in 3 or 4 equally divided doses; the lower dose may be adequate for small premature infants.VaginosisAdults
Intravaginal cream 1 applicatorful, preferably at bedtime, for 3 or 7 consecutive days in nonpregnant patients and 7 consecutive days in pregnant patients. Clindesse : 1 applicatorful any time of the day for 1 day. Intravaginal suppositories Insert 1 suppository/day, preferably at bedtime, for 3 consecutive days.
Store at controlled room temperature (68° to 77°F). Do not refrigerate oral solution (causes thickening). Discard any unused oral solution after 14 days.Topical gel, lotion, foam, and solution
Store at controlled room temperature (68° to 77°F). Store ClindaReach , Clindets , and ClindaMax gel and lotion between 59° and 86°F. Protect from freezing.Vaginal cream
Store at controlled room temperature (68° to 77°F). Store Clindesse vaginal cream between 59° and 86°F. Protect from freezing.Vaginal suppositories
Store at controlled room temperature (59° to 86°F). Avoid high humidity and temperatures higher than 86°F. Store Clindagel at 59° to 86°F. Do not store in direct sunlight.
Consult manufacturer's information for storage of diluted parenteral solutions.
May delay absorption of clindamycin.Erythromycin
May cause antagonism.Nondepolarizing neuromuscular blockers
May enhance actions of neuromuscular-blocking agents.
Aminophylline, ampicillin, barbiturates, calcium gluconate, magnesium sulfate, phenytoin sodium.
None well documented.
Hypotension; cardiopulmonary arrest after too-rapid IV use (rare).
Exfoliative dermatitis, hypersensitivity (eg, erythema multiforme; maculopapular rash; skin rash; urticaria; vesiculobullous rash, some cases resembling Stevens-Johnson syndrome [rare]), pruritus.
Abdominal pain; colitis, including pseudomembranous colitis (0.01% to 10% [more frequent with oral administration]); constipation, diarrhea, esophagitis, nausea, unpleasant or metallic taste (following higher doses of IV infusion); vomiting.Intravaginal
Azotemia, oliguria, proteinuria, UTI, vaginitis.Intravaginal
Fungal vaginosis (14%); vaginal moniliasis (13%); vulvovaginal disorder (7%); vulvovaginitis (6%); vulvovaginal pruritic vaginal pain (2%); trichomonas vaginitis, UTI (1%).
Agranulocytosis, eosinophilia, leukopenia, neutropenia, thrombocytopenia.
Jaundice, LFT abnormalities.
Induration, pain, sterile abscess, thrombophlebitis.Topical
Dryness (23%); oily skin (18%); erythema (16%); burning, itching, peeling (11%).
Back pain (2%).
Abnormal labor (vaginal); anaphylaxis; fungal infection.Intravaginal
Fungal infection (2%); abnormal labor, moniliasis (1%). Topical or vaginal use may theoretically produce adverse reactions seen with systemic use as a result of absorption.
Clostridium difficile –associated diarrhea (CDAD) can occur with clindamycin administration and may range in severity from mild diarrhea to fatal colitis. Because life-threatening colitis can occur, reserve clindamycin therapy for serious infections where less toxic antimicrobial agents are inappropriate. Clindamycin should not be used to treat nonbacterial infections such as most upper respiratory tract infections. C. difficile produces toxins that can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in patients with diarrhea following antibiotic use. CDAD has been reported to occur more than 2 months after therapy has been stopped. If CDAD is suspected or confirmed, discontinue the causative antibiotic and institute treatment (including fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile , and surgical evaluation).
MonitorBlood cell count/renal function/liver enzymes
Ensure that blood cell counts, liver enzymes, and renal function are determined periodically during prolonged therapy.Response to therapy
Monitor patient's response to therapy.Adverse reactions
Monitor patient for GI, skin, general body adverse reactions, and signs of superinfection.
Category B . Clindamycin does cross the placenta.
Excreted in breast milk.
Monitor organ system functions in newborns and children (16 yr of age and younger); parenteral form may contain benzyl alcohol, which can cause gasping syndrome in premature infants.Intravaginal
Safety and efficacy not established.Topical
Safety and efficacy not established in children younger than 12 yr of age.
May not tolerate diarrhea well (dehydration).
Use drug with caution in patients with asthma or significant allergies or who are atopic; anaphylactic/anaphylactoid reactions may occur.
Use drug with caution in patients with severe renal disease with severe metabolic aberrations.
Use drug with caution in patients with severe hepatic disease with severe metabolic aberrations.
Use with caution in patients with a history of GI disease or atopic patients.
May result in bacterial or fungal overgrowth of nonsusceptible organisms.
Some products contain tartrazine, which may cause allergic-type reactions in susceptible individuals.
May not tolerate diarrhea well (dehydration).
Drug does not diffuse into CSF. Do not use to treat meningitis.
Vaginal cream contains mineral oil, which may weaken latex rubber condoms or diaphragms.
No available information.
Copyright © 2009 Wolters Kluwer Health.